New research offers hope for treating Normal Tension Glaucoma
Glaucoma is the leading cause of irreversible blindness in the United States. While
the disease is commonly associated with elevated intraocular pressure, some patients
experience vision loss despite having normal eye pressure. This form of the disease,
known as Normal Tension Glaucoma, has puzzled researchers for years.
A recent study published in "Stem Cells" examined how a specific inherited gene mutation may contribute to normal tension glaucoma. Rather than elevated eye pressure damaging the optic nerve, the study found that retinal cells responsible for carrying visual information to the brain can become unhealthy after being overwhelmed by a defective protein.
Pinkal Patel, Ph.D., a postdoctoral research associate in Dr. Abbot Clark's laboratory, discusses the study and explains how these findings could shape future approaches to glaucoma treatment.
What stands out to you most about this study and its findings?
The unfolded protein response is the process cells use to manage and resolve the buildup of misfolded proteins, which are often caused by genetic mutations. Previous research has shown that mutations in the Myocilin gene trigger chronic UPR activation and cellular stress in the trabecular meshwork, the tissue at the front of the eye responsible for regulating eye pressure. Over time, this stress can lead to elevated eye pressure, damage to the optic nerve and retina, and ultimately vision loss.
Most studies investigating Myocilin mutations have focused on reducing UPR-related stress in the trabecular meshwork. This study takes a different approach by examining how mutant Myocilin affects retinal neurons, the cells responsible for transmitting visual information from the eye to the brain.
Dr. Patel notes that these findings broaden the field of glaucoma research by suggesting that reducing UPR-related cellular stress may help protect retinal neurons, opening the door to new neuroprotective treatment strategies.
While this study focuses on glaucoma occurring without elevated eye pressure, how do the results expand traditional thinking about the disease?
Current clinical evidence still supports lowering intraocular pressure as the most effective way to slow the progression of normal tension glaucoma. This suggests that retinal neurons in patients with normal tension glaucoma may be more vulnerable to even subtle changes in eye pressure, making pressure reduction below typical levels beneficial for slowing disease progression.
The findings from this study do not challenge the prevalent approach. More importantly, the study expands our understanding of glaucoma by highlighting additional molecular mechanisms that may directly contribute to retinal neuron damage. These findings encourage researchers to look beyond eye pressure alone when investigating the causes and treatment of glaucoma.
Could these findings influence how scientists approach treatment development or early detection of glaucoma?
UPR activation and cellular stress are common features of several forms of glaucoma. Targeting these pathways alongside traditional pressure-lowering treatments may provide additional neuroprotective benefits that have yet to be fully explored.
Because patients with normal tension glaucoma have eye pressures within the normal range, the disease can be difficult to detect before significant damage to the optic nerve and retinal neurons has occurred. In clinical practice, physicians often rely on a patient's family history, along with comprehensive eye examinations, to assess glaucoma risk and identify those who may benefit from closer monitoring.
From your perspective, what makes this research particularly promising for patients?
Glaucoma is a complex disease driven by multiple biological processes. Although lowering intraocular pressure remains the most effective treatment for slowing disease progression, it cannot restore vision or reverse the loss of retinal neurons that has already occurred.
Dr. Patel believes future treatment strategies may combine traditional pressure-lowering therapies with approaches that reduce UPR-related cellular stress. Such combination therapies could offer meaningful neuroprotection for certain patients with glaucoma.
"Medications that lower eye pressure are currently the mainstay of glaucoma treatment," Dr. Patel explains. "While they can slow disease progression, they cannot completely prevent or reverse neuronal loss. Neuroprotection remains one of the greatest unmet needs in glaucoma care, and we hope this study represents an important step toward achieving that goal."
To learn more about NTERI's vision research and commitment to advancing eye health, visit our website.